X @The Economist

Clinical Efficacy and Regulatory Approval - The new drug received official approval in the United States [1] - Trial results demonstrated that the treatment nearly doubles the median survival rate for patients with specific types of advanced pancreatic cancer [1] Industry Impact and Market Dynamics - The successful trial outcome breaks a decades-long deadlock in addressing one of the deadliest targets in oncology [1] - The scientific community responded with high acclaim, as reflected by a standing ovation from scientists [1]